TASE:TEVA

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citis 2025 Global Healthcare Conference in December

November 21, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) --…

2 weeks ago

Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November

October 31, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) --…

1 month ago

FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate…

2 months ago

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

September 25, 2025 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) --…

2 months ago

Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR®…

3 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

3 months ago